[Association of illicit drug use in pregnant women and congenital syphilis in a public hospital in Mexico]. / Asociación del consumo de drogas ilícitas en mujeres embarazadas y sífilis congénita en un Hospital Público de México.

We conducted a nested case-control study within a cohort with the aim of studying the association between illicit drug use and congenital syphilis (CS). Cases were diagnosed based on treponemal and non-treponemal tests conducted both in the mother and the newborn (NB). Multivariate analysis with logistic regression was performed. A total of 6171 births with a mean gestational age of 37.8 weeks were recorded and 62 CS events were diagnosed (incidence 10.5 events/1000 NB). Associated maternal factors were illicit drug use (OR 14.08, 95% CI 1.19-166.6), <5 prenatal visits (OR 2.9, 95% CI 1.12-7.53), more than two sexual partners (OR 3.76, 95% CI 1.62-8.71) and professional education level (OR 0.06, 95% CI 0.005-0.85). Among the mothers of the cases presented, the prevalence of illicit drug use was 22.6% and the most frequent drugs were methamphetamines and cannabis.

Case Report: Characterization of known (c.607G>C) and novel (c.416C>G) ELANE mutations in two Mexican families with congenital neutropenia.

The most common causes of congenital neutropenia are mutations in the ELANE (Elastase, Neutrophil Expressed) gene (19p13.3), mostly in exon 5 and the distal portion of exon 4, which result in different clinical phenotypes of neutropenia. Here, we report two pathogenic mutations in ELANE, namely, c.607G>C (p.Gly203Arg) and a novel variant c.416C>G (p.Pro139Arg), found in two Mexican families ascertained via patients with congenital neutropenia who responded positively to the granulocyte colony-stimulating factor (G-CSF) treatment. These findings highlight the usefulness of identifying variants in patients with inborn errors of immunity for early clinical management and the need to rule out mosaicism in noncarrier parents with more than one case in the family.

Poor Access to Liver Transplantation and Survival of Children With Acute Liver Failure, Acute-on-chronic Liver Failure or Chronic Liver Disease.

We describe the survival of children with acute liver failure (ALF), chronic liver disease (CLD), or acute-on-chronic liver failure (ACLF) with poor access to liver transplantation (LT). A retrospective cohort study of 42 patients <18 years of age was conducted in the Hospital Civil de Guadalajara "Dr. Juan I. Menchaca". The median age was 76 months; 57.1% were female, 40.5% presented with ALF, 35.7% with CLD, and 23.8% with ACLF. Also, 38.1% (16/42) presented liver disease of unknown etiology. Death occurred in 45.2%; 14.3% were transferred to another hospital, and none received LT. Mortality in ALF, CLD, and ACLF was 76%, 0%, and 60%, respectively. In the survival analysis, within the first 20 months after diagnosis, the mortality rate was greater than 50% with ALF. The importance of having referral programs that perform liver transplantation is highlighted by the poor prognosis of the patients, despite conservative treatment.

Mendelian Susceptibility to Mycobacterial Disease: Retrospective Clinical and Genetic Study in Mexico.

Mendelian susceptibility to mycobacterial disease (MSMD) is a rare genetic disorder characterized by impaired immunity against intracellular pathogens, such as mycobacteria, attenuated Mycobacterium bovis-Bacillus Calmette-Guérin (BCG) vaccine strains, and environmental mycobacteria in otherwise healthy individuals. Retrospective study reviewed the clinical, immunological, and genetic characteristics of patients with MSMD in Mexico. Overall, 22 patients diagnosed with MSMD from 2006 to 2021 were enrolled: 14 males (64%) and eight females. After BCG vaccination, 12 patients (70%) developed BCG infection. Furthermore, 6 (22%) patients developed bacterial infections mainly caused by Salmonella, as what is described next in the text is fungal infections, particularly Histoplasma. Seven patients died of disseminated BCG disease. Thirteen different pathogenic variants were identified in IL12RB1 (n = 13), IFNGR1 (n = 3), and IFNGR2 (n = 1) genes. Interleukin-12Rß1 deficiency is the leading cause of MSMD in our cohort. Morbidity and mortality were primarily due to BCG infection.

Congenital infection by cytomegalovirus in newborns with very low birth weight.

Not available.

Asociación de comorbilidades con infección sintomática y síndrome inflamatorio multisistémico por SARS-CoV-2 en niños / Association of comorbidities and symptomatic infection and multisystemic inflammatory syndrome due to SARS-CoV-2 in children

INTRODUCCIÓN: En niños, la infección por el nuevo coronavirus (SARS-CoV-2) habitualmente cursa asintomática o con síntomas leves; sólo una proporción menor presenta síntomas graves o un conjunto de signos y síntomas postinfecciosos descritos como síndrome inflamatorio multisistémico pediátrico (SIMP). OBJETIVO: Describir la asociación de comorbilidades con la infección sintomática y SIMP por SARS-CoV-2 en niños. PACIENTES Y MÉTODOS: Estudio transversal analítico, se incluyeron pacientes pediátricos hospitalizados. Mediante reacción de la polimerasa en cadena y/o pruebas antigénicas se diagnosticó la infección activa y con la definición propuesta por la Organización Mundial de la Salud se identificaron pacientes con SIMP. RESULTADOS: Se estudiaron 375 pacientes, la mediana de edad fue de 3,8 años. El 47,7% (n: 179) presentó comorbilidades, siendo las más frecuentes: neoplasias sólidas y/o enfermedades hematológicas 17,1% (n: 64), obesidad 13,3% (n: 48) y neumopatías crónicas 9,3% (n: 35). Presentaron infección por SARS-CoV-2 el 16,5% (n: 62/375) y SIMP el 10,4% (n. 39/375). Los niños con obesidad mostraron mayor riesgo de infección sintomática (OR 2,21, IC 95% 1,05-4,6) y en aquellos con cáncer (OR 0,15, IC 95% 0,03-0,68) el riesgo de SIMP fue menor. CONCLUSIONES: La presencia de comorbilidades modifica el riesgo de infección por SARS-CoV-2 y SIMP.

BACKGROUND: In children, infection by the new coronavirus (SARS-CoV-2) usually occurs asymptomatic or with mild clinical data, only a minor proportion have severe symptoms or a set of post-infectious signs and symptoms described as Pediatric Inflammatory Multisystemic Syndrome (PIMS). AIM: To describe the association of comorbidities with symptomatic infection and PIMS due to SARS-CoV-2 in children. METHODS: Analytical cross-sectional study, pediatric patients hospitalized were included. Active infection was diagnosed by polymerase chain reaction and/or antigenic tests. Patients with PIMS were identified by the definition proposed by the World Health Organization. RESULTS: 375 patients were studied, the median age was 3.8 years. 47.7% (n: 179) had comorbidities, the most frequent were: solid neoplasms and/or hematological diseases 17.1% (n: 64), obesity 13.3% (n: 48) and chronic pneumopathies 9, 3% (n: 35). SARS-CoV-2 infection was present in 16.5% (n: 62/375) and PIMS in 10.4% (n. 39/375). Children with obesity showed a higher risk of infection (OR 2.21, 95% CI 1.05-4.6) and in those with cancer (OR 0.15, 95% CI 0.03-0.68) the PIMS risk was lower. CONCLUSIONS: The presence of comorbidities modifies the risk of infection by SARS-CoV-2 and PIMS.

Expresión de infección por SARS-CoV-2 en niños: infección aguda sintomática y síndrome inflamatorio multisistémico.

No disponible.

[Association of comorbidities and symptomatic infection and multisystemic inflammatory syndrome due to SARS-CoV-2 in children]. / Asociación de comorbilidades con infección sintomática y síndrome inflamatorio multisistémico por SARS-CoV-2 en niños.

BACKGROUND: In children, infection by the new coronavirus (SARS-CoV-2) usually occurs asymptomatic or with mild clinical data, only a minor proportion have severe symptoms or a set of post-infectious signs and symptoms described as Pediatric Inflammatory Multisystemic Syndrome (PIMS). AIM: To describe the association of comorbidities with symptomatic infection and PIMS due to SARS-CoV-2 in children. METHODS: Analytical cross-sectional study, pediatric patients hospitalized were included. Active infection was diagnosed by polymerase chain reaction and/or antigenic tests. Patients with PIMS were identified by the definition proposed by the World Health Organization. RESULTS: 375 patients were studied, the median age was 3.8 years. 47.7% (n: 179) had comorbidities, the most frequent were: solid neoplasms and/or hematological diseases 17.1% (n: 64), obesity 13.3% (n: 48) and chronic pneumopathies 9, 3% (n: 35). SARS-CoV-2 infection was present in 16.5% (n: 62/375) and PIMS in 10.4% (n. 39/375). Children with obesity showed a higher risk of infection (OR 2.21, 95% CI 1.05-4.6) and in those with cancer (OR 0.15, 95% CI 0.03-0.68) the PIMS risk was lower. CONCLUSIONS: The presence of comorbidities modifies the risk of infection by SARS-CoV-2 and PIMS.

[Bloodstream infections with Candida glabrata in a neonatal intensive care unit that uses prophylaxis with fluconazole]. / Infección del torrente sanguíneo por Candida glabrata en una unidad de cuidados intensivos neonatales con prescripción de profilaxis con fluconazol.

BACKGROUND: Candida glabrata is an emerging pathogen with the ability to develop tolerance and resistance to azole antifungals, which creates uncertainty about the usefulness of antifungal prophylaxis in newborns. AIMS: The aim of this study was to describe the factors associated with C. glabrata infection in a NICU that uses prophylaxis with fluconazole. METHODS: A case-control study paired by gestational age was designed and conducted at the Civil Hospital of Guadalajara Dr. Juan I. Menchaca. Newborns with C. glabrata infection were studied and for each one a matched control was selected by gestational age. Odds ratios (OR) were estimated with 95% confidence intervals (95% CI) and McNemar test for contrast of hypothesis was applied. RESULTS: Twenty-one infected patients were identified, from whom 66.7% were male; the median gestational age was 31.5 weeks. Increased risk of infection with C. glabrata was observed when there was a prescription of more than one antimicrobial scheme (OR 21, 95% CI, 1.23 - 358.3; p=0.006) and also among patients with surgical comorbidities (OR 8, 95% CI 1.01 - 63.9; p=0.04). During the study period, exposure to fluconazole showed no difference in the risk of infection. CONCLUSIONS: Neonates with more than one antimicrobial regimen and those with surgical comorbidities had a higher risk of C. glabrata infection.

Infección del torrente sanguíneo por Candida glabrata en una unidad de cuidados intensivos neonatales con prescripción de profilaxis con fluconazol / Bloodstream infections with Candida glabrata in a neonatal intensive care unit that uses prophylaxis with fluconazole

ANTECEDENTES: Candida glabrata es un patógeno emergente con capacidad de desarrollar tolerancia y resistencia a los antifúngicos azólicos, lo que genera incertidumbre sobre la utilidad de la profilaxis antifúngica en recién nacidos. OBJETIVOS: El objetivo de este estudio fue describir los factores asociados a la infección por C. glabrata en una UCIN que utiliza la profilaxis con fluconazol. MÉTODOS: Se diseñó un estudio de casos y controles pareado por edad gestacional realizado en el Hospital Civil de Guadalajara Dr. Juan I. Menchaca. Se estudiaron los recién nacidos con infección por C. glabrata y para cada uno se seleccionó un control pareado por edad gestacional; se estimaron razones de momios (RM) con intervalos de confianza del 95% (IC 95%) y prueba de McNemar para contraste de hipótesis. RESULTADOS: Veintiún pacientes presentaron infección, con el 66,7% de ellos de género masculino; la mediana de edad gestacional fue de 31,5 semanas. Se observó mayor riesgo de infección por C. glabrata cuando hubo prescripción de más de un esquema antimicrobiano (RM 21, IC 95% 1,23 - 358,3; p = 0,006) y en pacientes con comorbilidades quirúrgicas (RM 8, IC 95% 1,01 - 63,9; p = 0,04). Durante el periodo de estudio el riesgo de infección no se vio aumentado por la exposición a fluconazol. CONCLUSIONES: Presentaron mayor riesgo de infección por C. glabrata los neonatos con más de un esquema antimicrobiano y aquellos con comorbilidades quirúrgicas

BACKGROUND: Candida glabrata is an emerging pathogen with the ability to develop tolerance and resistance to azole antifungals, which creates uncertainty about the usefulness of antifungal prophylaxis in newborns. AIMS: The aim of this study was to describe the factors associated with C. glabrata infection in a NICU that uses prophylaxis with fluconazole. METHODS: A case-control study paired by gestational age was designed and conducted at the Civil Hospital of Guadalajara Dr. Juan I. Menchaca. Newborns with C. glabrata infection were studied and for each one a matched control was selected by gestational age. Odds ratios (OR) were estimated with 95% confidence intervals (95% CI) and McNemar test for contrast of hypothesis was applied. RESULTS: Twenty-one infected patients were identified, from whom 66.7% were male; the median gestational age was 31.5 weeks. Increased risk of infection with C. glabrata was observed when there was a prescription of more than one antimicrobial scheme (OR 21, 95% CI, 1.23 - 358.3; p = 0.006) and also among patients with surgical comorbidities (OR 8, 95% CI 1.01 - 63.9; p = 0.04). During the study period, exposure to fluconazole showed no difference in the risk of infection. CONCLUSIONS: Neonates with more than one antimicrobial regimen and those with surgical comorbidities had a higher risk of C. glabrata infection

[Prevalence of extended-spectrum beta-lactamases in enterobacteria of neonatal sepsis and associated factors]. / Prevalencia de ß-lactamasas de espectro extendido en enterobacterias causantes de sepsis neonatal y factores asociados.

BACKGROUND: Infections caused by extended-spectrum beta-lactamases enterobacteria (ESBL-EP) have implications for neonatal morbidity and mortality. AIM: To describe the prevalence of ESBL-EP in neonatal sepsis and associated factors. METHODS: A prospective cohort study was conducted from August 2016 to August 2017; newborn babies (NB) hospitalized in the Hospital Civil de Guadalajara "Dr. Juan I. Menchaca" were included. The ESBL-EP were investigated by double-disk synergy test and its association with clinical and demographic characteristics of the NB. RESULTS: A total of 1,501 hospitalized NB were studied, with an average gestational age of 36.3 weeks. They were diagnosed 196 neonatal sepsis events, the most frequent etiologies were enterobacteria (45.5%). Resistance to ampicilin was found in 88.8% and to broad spectrum cephalosporins in more than 42% of the strains; 22.9% of them were ESBL phenotype. Apgar ≤ 7 at five minutes of life (OR 4.6; 95% CI 1.47-14.6) and gestational age < 37 weeks (OR 5.4; 95% CI 1.04-27.) increase the risk. CONCLUSION: In enterobacteria that cause neonatal sepsis, 22.9% were EP-ESBL; infection was more likely in patients with Apgar ≤ 7 at five minutes of age and in preterm infants.

Tratamiento tardío de la intoxicación por paraquat en pacientes pediátricos: Reporte de dos casos / Late treatment of paraquat poisoning in pediatric patients: Report of two cases

El paraquat (PQ) pertenece al grupo de herbicidas de los bipiridilos. Su presentación es en forma líquida o en granulado, usándose con una concentración al 5 %, para uso en jardinería y al 20 % para uso agrícola. En la intoxicación en humanos el órgano blanco es el pulmón. Los pacientes desarrollan insuficiencia respiratoria que puede explicarse por una inicial actividad que involucra un gran estrés oxidativo, con presencia de radicales libres de oxígeno y peroxidación lipídica, con sus consecuentes daños, además de infiltración por polimorfonucleares que con su reacción de liberación empeoran la neumonitis. Puede haber mejoría de la neumonitis y el daño en algunos órganos, pero pronto la aparición de fibrosis pulmonar lleva a falta de respuesta a la administración de oxígeno y a la muerte por insuficiencia respiratoria en algunos días a semanas. De acuerdo con la cantidad ingerida varía la evolución de la severidad del cuadro clínico. Se presentan dos pacientes pediátricos con intoxicación por PQ, a quienes se les inició tratamiento inmunosupresor después de 48 horas de la exposición. Uno de los pacientes se intoxicó de manera no intencional y otro por suicidio. Los dos pacientes recibieron tratamiento similar, sin embargo, el paciente con intención suicida falleció días después de la exposición. Se hace una revisión de la literatura sobre el tratamiento administrado.

Paraquat (PQ) belongs to the bipyridyls herbicides. Its presentation is liquid or granulated, being used at concentrations of 5 %, in gardening and 20 % in agricultural use. In human poisoning, the target organ is the lung. The patients develop respiratory insufficiency that can be explained by an initial activity that involves a great oxidative stress, with the presence of oxygen free radicals and lipid peroxidation, with its consequent damages, in addition to polymorphonuclear infiltration that with its liberation reaction worsen pneumonitis. There may be improvement of pneumonitis, but the appearance of pulmonary fibrosis will lead to a lack of response to the administration of oxygen and death due to respiratory failure in a few days to a few weeks. According to the amount ingested, the evolution of the severity of the clinical picture varies. We present two pediatric patients with PQ poisoning, who were started on immunosuppressant treatment after 48 hours of exposure. One of the patients was poisoned incidentally and the other one by suicide. The two patients received similar treatment, however, the patient with suicidal intention died days after the exposure. A review of the literature on the treatment offered is made.

Morbimortalidad neonatal en un entorno de baja adherencia a corticosteroides prenatales / Neonatal morbidity and mortality associated with low adherence to prenatal corticosteroids

Introducción: Los corticosteroides prenatales disminuyen la morbimortalidad neonatal, sin embargo, existen pocos estudios en países en vías de desarrollo, con resultados no consistentes. El objetivo fue cuantificar la frecuencia del uso de corticosteroides prenatales y estimar su efecto en la morbimortalidad de recién nacidos prematuros. Métodos: Estudio de cohorte retrospectivo; se seleccionaron los recién nacidos prematuros de un censo realizado entre enero de 2016 y agosto de 2017. De los expedientes maternos se registró el uso de corticosteroides; y de los expedientes de los neonatos se indagó las variables dependientes. La asociación se analizó con regresión logística, ajustada a la edad gestacional y el peso. Resultados: Se estudiaron 1.083 prematuros, el 53,3% de género masculino; la edad gestacional promedio fue 33,4 semanas. Recibieron corticosteroides el 42%, con latencia ≥ 24 horas el 23,6% y ≥ 48 horas el 13,8%. Presentaron síndrome de dificultad respiratoria el 35% (379/1083), sepsis neonatal temprana el 4,4% (48/1083), sepsis neonatal tardía el 10,7% (116/1083), hemorragia intraventricular el 15,1% (137/908), enfermedad pulmonar crónica el 51,4% (165/321) y muerte el 22,3% (242/1083). Los corticosteroides prenatales disminuyeron el riesgo de muerte en menores de 34 semanas (OR: 0,63, IC 95%: 0,40-0,98); el decremento fue mayor si presentaron latencia ≥ 48 horas (OR: 0,40; IC 95%: 0,20-0,80). El resto de variables dependientes no se modificó por la intervención. Conclusiones: El 42% de los prematuros recibe corticosteroides prenatales. En menores de 34 semanas se observó una disminución del riesgo de muerte sin modificación en la morbilidad

Introduction: Prenatal corticosteroids reduce neonatal mortality and morbidity; however, there are few studies in developing countries, and with inconsistent results. The purpose of this study was to quantify the frequency of the use of prenatal corticosteroids and to estimate its effect on the morbidity and mortality of premature newborns. Methods: A retrospective cohort study was performed on premature newborns selected from a census conducted between January 2016 and August 2017. The use of corticosteroids was taken from the maternal records, and the dependent variables from the neonatal records. An analysis was made of the relationship using logistic regression, adjusted to gestational age and weight. Results: The study included 1083 premature infants of which 53.3% were male. The mean gestational age was 33.4 weeks. Corticosteroids were received by 42%, with latency ≥ 24 hours in 23.6% and ≥ 48 hours in 13.8%. Respiratory distress syndrome was observed in 35% (379/1083), early neonatal sepsis in 4.4% (48/1083), late neonatal sepsis in 10.7% (116/1083), intraventricular haemorrhage in 15.1% (137/908), chronic lung disease in 51.4% (165/321), and death in 22.3% (242/1083). Prenatal corticosteroids decreased the risk of death in children under 34 weeks (OR 0.63, 95% CI 0.40-0.98). The decrease was greater if they presented with latency ≥ 48 hours (OR 0.40, 95% CI 0.20-0.80). The rest of the dependent variables were not modified by the intervention. Conclusions: In preterm infants, 42% received antenatal corticosteroids. In those with less than 34 weeks, there was a decrease in the risk of death without changes in morbidity

Prevalencia de β -lactamasas de espectro extendido en enterobacterias causantes de sepsis neonatal y factores asociados / Prevalence of extended-spectrum beta-lactamases in enterobacteria of neonatal sepsis and associated factors

Resumen Introducción: Las infecciones causadas por enterobacterias productoras de β-talactamasas de espectro extendido (EP-BLEE) tienen implicaciones sobre la morbilidad y mortalidad neonatal. Objetivo: Describir la prevalencia de EP-BLEE en sepsis neonatal y los factores asociados. Métodos: Estudio de cohorte prospectivo, desde agosto del 2016 a agosto del 2017. Se incluyeron recién nacidos (RNs) ingresados en el Hospital Civil de Guadalajara "Dr. Juan I. Menchaca". Mediante prueba de difusión de doble disco se indagó la presencia de EP-BLEE y su asociación con características clínicas y demográficas de los RNs. Resultados: Se estudiaron 1.501 RNs hospitalizados, con edad gestacional promedio de 36,3 semanas. Se diagnosticaron 196 eventos de sepsis neonatal, la etiología más frecuente fueron enterobacterias (45,5%); 88,8% demostraron resistencia a ampicilina y más de 42% a cefalosporinas de amplio espectro. El 22,9% presentó fenotipo BLEE positivo. Tener Apgar ≤ 7 a los cinco minutos de vida (OR 4,6; IC 95% 1,47-14,6) y edad gestacional < 37 semanas (OR 5,4; IC 95%1,04-27,7) incrementaron el riesgo. Conclusión: En las enterobacterias causantes de sepsis neonatal, 22,9% son EP-BLEE; la infección es más probable en pacientes con Apgar ≤ 7 a los cinco minutos de vida y en prematuros.

Background: Infections caused by extended-spectrum beta-lactamases enterobacteria (ESBL-EP) have implications for neonatal morbidity and mortality. Aim: To describe the prevalence of ESBL-EP in neonatal sepsis and associated factors. Methods: A prospective cohort study was conducted from August 2016 to August 2017; newborn babies (NB) hospitalized in the Hospital Civil de Guadalajara "Dr. Juan I. Menchaca" were included. The ESBL-EP were investigated by double-disk synergy test and its association with clinical and demographic characteristics of the NB. Results. A total of 1,501 hospitalized NB were studied, with an average gestational age of 36.3 weeks. They were diagnosed 196 neonatal sepsis events, the most frequent etiologies were enterobacteria (45.5%). Resistance to ampicilin was found in 88.8% and to broad spectrum cephalosporins in more than 42% of the strains; 22.9% of them were ESBL phenotype. Apgar ≤ 7 at five minutes of life (OR 4.6; 95% CI 1.47-14.6) and gestational age < 37 weeks (OR 5.4; 95% CI 1.04-27.) increase the risk. Conclusion: In enterobacteria that cause neonatal sepsis, 22.9% were EP-ESBL; infection was more likely in patients with Apgar ≤ 7 at five minutes of age and in preterm infants.

[Neonatal morbidity and mortality associated with low adherence to prenatal corticosteroids]. / Morbimortalidad neonatal en un entorno de baja adherencia a corticosteroides prenatales.

INTRODUCTION: Prenatal corticosteroids reduce neonatal mortality and morbidity; however, there are few studies in developing countries, and with inconsistent results. The purpose of this study was to quantify the frequency of the use of prenatal corticosteroids and to estimate its effect on the morbidity and mortality of premature newborns. METHODS: A retrospective cohort study was performed on premature newborns selected from a census conducted between January 2016 and August 2017. The use of corticosteroids was taken from the maternal records, and the dependent variables from the neonatal records. An analysis was made of the relationship using logistic regression, adjusted to gestational age and weight. RESULTS: The study included 1083 premature infants of which 53.3% were male. The mean gestational age was 33.4 weeks. Corticosteroids were received by 42%, with latency ≥24hours in 23.6% and ≥48hours in 13.8%. Respiratory distress syndrome was observed in 35% (379/1083), early neonatal sepsis in 4.4% (48/1083), late neonatal sepsis in 10.7% (116/1083), intraventricular haemorrhage in 15.1% (137/908), chronic lung disease in 51.4% (165/321), and death in 22.3% (242/1083). Prenatal corticosteroids decreased the risk of death in children under 34 weeks (OR 0.63, 95% CI 0.40-0.98). The decrease was greater if they presented with latency ≥48hours (OR 0.40, 95% CI 0.20-0.80). The rest of the dependent variables were not modified by the intervention. CONCLUSIONS: In preterm infants, 42% received antenatal corticosteroids. In those with less than 34 weeks, there was a decrease in the risk of death without changes in morbidity.